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Abstract 
 
Acarbose，which is clinically widely used to treat Type 2 Diabetes，is thought to act at the small intestine by 
competitively inhibiting enzymes that delay the release of glucose from complex carbohydrates, thereby specifically reducing 
post prandial glucose excursion. The major side-effect of treatment with acarbose, flatulence, occurs when undigested 
carbohydrates are fermented by colonic bacteria, resulting in considerable amount of hydrogen. We propose that enteric 
benefits of  acarbose is partly attributable to be their ability to neutralise oxidative stress via increased production of H2 in 
the gastrointestinal tract. Therefore, symptoms of ulcerative colitis in human beings can be ameliorated by acarbose. 
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Introduction 
 
    Ulcerative colitis (UC), with its causes still not fully understood, is a chronic inflammatory disease affecting the 
rectum and the colon to a variable extent and exerts a substantially negative impact on the quality of life of affected patients 
who suffer a 10% increased risk in developing colon carcinoma. Although some progress has been made in the treatment of 
UC in the last decades and many conventional medical treatments such as sulfaslazine,corticosteroids and 
immunosuppression are introduced into UC treatments from different aspects of UC etiologic process (Hawthorne et al.,2008; 
Carty,et al.,2003). Unfortunately, all these medicines have side-effects. People have to suffer from the sever adverse effects 
and the course of UC is still characterized by periods of remission interspersed with exacerbations (Solberg et al.,2008). 
    The expression of UC is generally believed to associate with the interplay of environmental, genetic and 
immunological factors (Fries et al.,2011). However, there is still not an integrated concept which explains the initiating 
event(s) and/or fundamental abnormalities in UC related to the pathophysiological changes. It does seem certain that UC is 
amplified and propagated by an uncontrolled and sustained host immune response, as the disease is paralleled by an extensive 
inflammatory infiltrate in the lamina propria, consisting of polymer phonuclear neutrophils, eosinophils and plasma cells. 
Whereas, the final steps resulting from such an excessive and enduring mucosal immune activation to tissue injury are still 
not fully confirmed. Ultimately, only a limited number of effector mechanisms, including reactive oxygen metabolites 
(ROM), might be responsible for the excessive cellular/tissue damage, chronic inflammation and destruction of normal tissue 
is observed in UC (Karp et al.,2006). Impaired antioxidant mechanism is implicated as one of pathogenic causes of UC. 
Inflamed tissues generate hydroxyl radicals, the most cytotoxic reactive oxygen species (ROS), which up-regulate TNF-α 
expression  through  NF-kB  signaling  pathway and activate NADPH-Oxygenase (NOX) expression, increasing ROS 
production as a vicious circle (Gloire et al.,2006; Moe,et al.,2006). 
    In principle, excessive generation of ROM may lead to the attack and damage of all cellular and extracellular 
components (Roessner et al.,2008). However, it is important to realize that the overall high reactivity and short half-life of 
ROM implies that the inflicted tissue damage is generally close to the site of ROM generation. In UC, activated macrophages 
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and neutrophils which produce excessive ROS aggregate in the inflaming gut and severe oxidative stress will occur 
subsequently. When exceeding the antioxidative ability of the intestinal antioxidant defense system, ROS will cause 
substantial damages in membrane lipid ,protein, and DNA, making the oxidative stress injuries in patients with UC worse and 
worse (Grisham et al.,1998). Since both inflammation and oxidation processes are reciprocally connected, antioxidants are 
viewed as a promising therapy for UC that can significantly alleviate the symptoms, i.e. body weight loss, visible fecal blood 
and diarrhea (HS et al.,2005). Therefore, the world has focused on finding new antioxidants in UC treatment . 
 
Molecular hydrogen (H2):a novel hotspot of antioxidant and inflammation suppressor 
 
    In recent years, experimental evidences have proved that molecular hydrogen (H2) acts as a novel antioxidant and 
inflammation suppressor with the following interesting properties(Ohsawa et al.,2007): (1) H2 can permeates cell membranes 
and target the cellular organelles, including the mitochondria and nuclei (Li et al.,2012); (2) H2 specifically quenches 
detrimental ROS, such as ·OH and peroxynitrite (ONOO-), while maintaining the metabolic oxidation-reduction reaction and 
their less-potent ROS, such as O2- , H2O2 and nitric oxide (NO
·) (Chen et al., 2011). It could be very important in clinics in 
the future that H2 could selectively react with exclusively detrimental ROS, such as hydroxyl radical and peroxynitrite, 
exerting protective effects. H2 did not react with other physiological ROS, such as superoxide anion and H2O2, which possess 
physiological roles. Therefore, unlike the other antioxidant supplements with strong reductive reactivity, H2 is mild enough 
without disturbing metabolic oxidation-reduction reactions or disrupting Oxidative Stress (OS) involved in cell signaling 
(Yoshida et al.,2012). Additionally, as H2 is electrically neutral and much smaller than the oxygen molecule, it easily 
penetrates membranes and enters cells and organelles such as nucleus and mitochondria (Kawai et al.,2012). This is 
particularly important, as the latter is the primary site of ROS generation and notoriously difficult to target, and hydrogen 
could diffuse freely within the body, without any side effects (Ohta.,2011). H2 can be administered orally in the form of 
H2-dissolved saline. Mikihito Kajiya reported that the administration of saturated hydrogen water for 7days reduced the 
levels of several biomarkers of proinflammatory cytokine, such as IL-12 ,TNF-αand IL-1β(Kajiya et al., 2009). In other 
experiments, hydrogen gas treatment has significant protective effects on schistosomiasis associated chronic liver 
inflammation and H2-rich saline treatment significantly attenuates the severity of L-Arg-induced acute pancreatitis by 
ameliorating the increased serum amylase activity, inhibiting neutrophils infiltration and lipid oxidation (Chen et al.,2010). 
Therapeutic effects of H2 have been confirmed in the cell damage after stroke, ischemia-reperfusion injuries，transplantation 
injuries and other injuries related to oxidative stress (Hayashida et al.,2008; Fukuda,et al.,2007). Thus, H2 can protect cells 
from oxidative stress injuries. In inflammation process, H2 mediates suppression of proinflammatory cytolcines, especially 
IL-1β, TNF-α, IL-6 in inflammatory tissues. These research results suggest that persistent intake of H2 has the potential to 
reduce oxidative stress and may treat UC. 
 
Acarbose : facilitate H2 generated in gastrointestinal tract and ameliorates symptoms of UC  
 
    Acarbose is an α-glucosidase inhibitor acting specifically at the level of postprandial glucose excursion. This 
compound lowers HbA1c by 0.5-1% in patients with Type 2 diabetes, either drug naive or in combination with other 
antidiabetic drugs. In those with impaired glucose tolerance (IGT), it reduces the incidence of newly diagnosed diabetes by 
36.4% (Chiasson et al., 2003). Furthermore, it has beneficial effects on overweight, reduces blood pressure and triglycerides, 
and downregulates biomarkers of low-grade inflammation (Hanefeld et al.,2004). The major side-effect of treatment with 
α-glucosidase inhibitors, flatulence, occurs when undigested carbohydrates are fermented by colonic bacteria, resulting in gas 
formation. The reason of flatulence is thought to act at the small intestine by competitively inhibiting enzymes that delay the 
release of glucose from complex carbohydrates, thereby specifically reducing post prandial glucose excursion. Then 
spontaneous production of H2 gas in the human body occurs via the fermentation of undigested carbohydrates by the resident 
enterobacterial flora (Yoshihiko et al., 2009). 
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    H2 is not produced endogenously in mammalian cells, since the hydrogenase activity responsible for the formation 
of H2 gas may not be present (Stephen et al., 2012). Instead, spontaneous production of H2 gas in the human body occurs via 
the fermentation of undigested carbohydrates by the resident enterobacterial flora. H2 is transferred to the portal circulation 
and excreted through the breath in significant amounts (Michael et al.,1969). Flatulence is regarded as the major side-effect 
of treatment with acarbose (Ladas et al., 1992). Yoshihiko Suzuki reported that acarbose treatment significantly increased the 
amount of exhaled H2 by detecting in eleven healthy volunteers (10 males and 1 female) who were administered acarbose at a 
dosage of 300 mg/day (100 mg three times a day) for 4 days under free-feeding conditions. Kajiyama treated patients with 
type 2 diabetes or impaired glucose tolerance with 900ml/day (300ml three times a day) H2-dissolved water. After drinking 
300 ml of H2-dissolved water, the exhaled H2 gas concentration reached a maximum of 56±27.8 ppm at 15 min, and 
returned to the baseline level at 150 min (Kajiyama et al.,2008). This peals level of H2 gas reduced the levels of oxidative 
stress biomarkers and improved glucose metabolism in patients with type 2 diabetes or impaired glucose tolerance. 
Considering that gastrointestinal tract derived H2 , which is closely related to reduced cardiovascular events, could reduce 
general oxidative stress injuries, we assume that the induced H2 by acarbose might be the key to the symptoms alleviation in 
UC by cutting Myeloperoxidase (MPO) level. 
According to the published data in 2009, mice UC induced by dextran sodium sulfate (DSS) was treated with saturated 
hydrogen water for 7 days. The study demonstrated that H2 could attenuate DSS-induced colitis by down-regulating the 
expression of proinflammatory cytokines, as well as suppressing the infiltration of macrophages in the colon lesion. The 
administration of H2 remarkably reduced the  clinical  symptoms  of  DSS-induced  colitis, i.e., body weight loss, 
visible fecal blood and diarrhea, colitis score, and shortening of colon length. Histopathological evaluation further supported 
the effects of H2 on the prevention of DSS-mediated destruction of epithelium crypt structure. These observations clearly 
indicate that the amounts of H2 gas generated by acarbose are sufficient to reduce systemic oxidative stress. Oral 
administration of acarbose may be superior to drinking H2-rich water in terms of maintenance of the appropriate H2 gas levels 
in the body. 
 
Conclusion 
 
    Based on these observations and experimental results, H2 has been proved effective in DSS-induced mice colitis 
and acarbose was thought to generate H2 in gastrointestinal tract .Therefore, we hypothesize that acarbose may be a novel and 
promising therapeutic option for UC as an indirect antioxidant. It may significantly restrict inflammation and alleviate clinical 
UC symptoms, improving the life quality of patients,and that these benefits can be attributed at least in part to the abilities of 
acarbose to neutralise oxidative stress by increasing the production of H2 in the gastrointestinal tract. Although acarbose 
probably has many other beneficial antioxidant effects on other diseases such as transplantation induced organs injury, 
cardiovascular diseases, cerebrovascular accidents etc., we still need to further study the biological mechanism. 
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